Clearside Biomedical Q3 2024 Earnings Report $0.94 -0.01 (-1.06%) As of 10:55 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Earnings HistoryForecast Clearside Biomedical EPS ResultsActual EPS-$0.10Consensus EPS -$0.14Beat/MissBeat by +$0.04One Year Ago EPS-$0.15Clearside Biomedical Revenue ResultsActual Revenue$1.04 millionExpected Revenue$0.25 millionBeat/MissBeat by +$790.00 thousandYoY Revenue GrowthN/AClearside Biomedical Announcement DetailsQuarterQ3 2024Date11/12/2024TimeAfter Market ClosesConference Call ResourcesConference CallCLSD Earnings History Clearside Biomedical Earnings HeadlinesClearside Biomedical Announces Multiple Medical Meeting Presentations Focused on the Advantages of Suprachoroidal Delivery and Key Differentiators in its CLS-AX Clinical ProgramJanuary 28 at 7:05 AM | globenewswire.comClearside Biomedical announces ARCATUS approved in Australia, SingaporeJanuary 23, 2025 | markets.businessinsider.comYour chance to get on the next “60-Second Trade”Even retirees are being forced back to work just to keep up. And if you're waiting for help from the Fed or government... Well, you might be waiting a very long time. But Roger Scott has uncovered something interesting... What if there was a way to fight back against inflation? A simple method you could use right from your phone...January 31, 2025 | WealthPress (Ad)Clearside Biomedical Announces its Asia-Pacific Partner, Arctic Vision, Received Approval of Suprachoroidal Treatment for Uveitic Macular Edema in Australia and SingaporeJanuary 22, 2025 | globenewswire.comClearside announces publication of insights on drug development, regulationDecember 20, 2024 | finance.yahoo.comClearside Biomedical Announces Publication of Critical Insights into Retinal Drug Development in the Peer-Reviewed Scientific Journal, EyeDecember 19, 2024 | globenewswire.comSee More Clearside Biomedical Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Clearside Biomedical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Clearside Biomedical and other key companies, straight to your email. Email Address About Clearside BiomedicalClearside Biomedical (NASDAQ:CLSD), a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.View Clearside Biomedical ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Why Amazon’s Next Earnings Could Trigger a Stock BreakoutS&P 500 Earnings Set to Shine: January's Critical Market TestCiena Rebounds: AI and Strong Guidance Drive Post-Earnings SurgeHistory Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead? Upcoming Earnings PayPal (2/3/2025)Palantir Technologies (2/3/2025)NXP Semiconductors (2/3/2025)Mitsubishi UFJ Financial Group (2/3/2025)Mondelez International (2/4/2025)Advanced Micro Devices (2/4/2025)Alphabet (2/4/2025)Alphabet (2/4/2025)Amgen (2/4/2025)Banco Bilbao Vizcaya Argentaria (2/4/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
